^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Nasopharyngeal Carcinoma
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Nasopharyngeal cancer: Recurrent/Unresectable or Metastatic (with no surgery or RT option)…Other Recommended Regimens (First-Line)…Carboplatin/Cetuximab
    Secondary therapy:
    carboplatin